A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-ov7/ ENGOT-ov80 Study)
Conditions: Ovarian Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Vulvar Cancer; Vagina Neoplasm; Clear Cell Carcinoma Interventions: Drug: Dostarlimab; Drug: Bevacizumab; Drug: Doxorubicin; Drug: Gemcitabine; Drug: Paclitaxel Sponsor: Yonsei University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Avastin | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Clear Cell Carcinoma | Research | Study